Buckingham Research Downgrades Emerson (EMR) to Underperform
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
Buckingham Research downgraded Emerson (NYSE: EMR) from Neutral to Underperform with a price target of $44.00.
Shares of Emerson closed at $54.67 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan Downgrades ARIAD Pharmaceuticals (ARIA) to Underweight
- Mizuho Securities Downgrades Teva Pharma (TEVA) to Neutral
- RBC Capital Downgrades Time Warner (TWX) to Sector Perform
Create E-mail Alert Related CategoriesDowngrades, Hot Downgrades
Related EntitiesBuckingham Research
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!